Industry
Biotechnology
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Loading...
Open
8.86
Mkt cap
371M
Volume
63K
High
8.92
P/E Ratio
-3.01
52-wk high
18.40
Low
8.38
Div yield
N/A
52-wk low
4.42
Portfolio Pulse from Henry Khederian
October 25, 2024 | 2:54 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 12:19 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 12:03 pm
Portfolio Pulse from Avi Kapoor
October 24, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 3:54 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 10:34 am
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 3:32 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 8:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.